PML and acute promyelocytic leukemia: The past 30 years have seen rapid progress in classical APL treatment by using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) to target the PML::RARA fusion protein, converting the disease from highly lethal to highly curable (7, 8).